Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DANFLU-1: High-Dose vs Standard-Dose Influenza Vaccine
NCT05048589Phase 2Completed
- Start
- Oct 2021
- Primary completion
- May 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of Efluelda in influenza. Started Oct 2021; status: completed.
02
Drugs
Efluelda
03
Conditions
influenza
Beyond the preview
Go deeper on NCT05048589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05048589.